Analysis-Innovent's weight-loss drug highlights China challenge for Novo, Lilly

Analysis-Innovent’s weight-loss drug highlights China challenge for Novo, Lilly

By Andrew Silver SHANGHAI (Reuters) -Innovent Biologics’ newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction. Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo…

Read More
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today

Why Eli Lilly (LLY) Shares Are Getting Obliterated Today

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase. The pharmaceutical company announced late-stage trial data for its oral weight-loss pill, orforglipron, which showed an average weight loss of 12.4%. This…

Read More
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups

Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups

A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. “Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,” said Tony Ren, head…

Read More